| Page 5 | Kisaco Research
 

Raju Pusapati

Vice President, Life Sciences
Solix Technologies Inc.

Dr. Raju Pusapati is a biologist and drug discovery scientist with a distinguished 15+ year career spanning top-tier institutions like Genentech, Exelixis, and emerging biotech ventures. Trained at Harvard and Genentech, his expertise lies in translating basic cancer biology—including the discovery of novel signaling pathways and resistance mechanisms—into viable clinical candidates.

Raju Pusapati

Vice President, Life Sciences
Solix Technologies Inc.

Raju Pusapati

Vice President, Life Sciences
Solix Technologies Inc.

Dr. Raju Pusapati is a biologist and drug discovery scientist with a distinguished 15+ year career spanning top-tier institutions like Genentech, Exelixis, and emerging biotech ventures. Trained at Harvard and Genentech, his expertise lies in translating basic cancer biology—including the discovery of novel signaling pathways and resistance mechanisms—into viable clinical candidates.

As a project leader and biology lead, he has a proven track record of steering oncology programs from target validation and lead identification through to Go/No-Go decisions, with publications in top-tier journals such as Cancer Cell and Nature Chemical Biology. His hands-on experience encompasses the full spectrum of pre-clinical work, including biomarker strategy, PK/PD, and managing complex internal and external collaborations.

In his current role as Vice President of Life Sciences at Solix Technologies, Dr. Pusapati leverages this deep industry background to bridge the gap between biology and technology. He leads the charge in adopting Solix's CDP and Enterprise AI platforms, empowering life sciences companies to unlock data-driven insights and accelerate therapeutic innovation. He brings this unique, dual perspective to the panel “AI and Multi-omics Integration for Enhanced Target Identification and Validation".

How Pharma Teams Operationalize OMICS Foundation Models in Early Discovery

Author:

Rick Schneider

CEO
Helical

Rick Schneider

CEO
Helical
 

Rick Schneider

CEO
Helical

Rick Schneider

CEO
Helical

Rick Schneider

CEO
Helical
 

Juan Felipe Beltran

Associate Director AI/Machine Learning
BullFrog AI

Juan Felipe Beltran

Associate Director AI/Machine Learning
BullFrog AI

Juan Felipe Beltran

Associate Director AI/Machine Learning
BullFrog AI
gloss

In the increasing demand of personalisation and efficacy, discover how formulations and adaptive energy technology converge to create the future of beauty. Learn how your brand can accelerate personalized skincare innovation through predictive skin modelling.

Author:

Dr. Marc Clement

Co-Founder/Chief Innovation Officer
CyDen Ltd

Dr. Marc Clement

Co-Founder/Chief Innovation Officer
CyDen Ltd